Akari Therapeutics PLC (AKTX) - Total Assets
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) holds total assets worth $47.89 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Akari Therapeutics PLC reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Akari Therapeutics PLC - Total Assets Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. Check AKTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Akari Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Akari Therapeutics PLC's total assets of $47.89 Million consist of 11.4% current assets and 88.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.00 Million | 71.0% |
| Goodwill | $8.43 Million | 17.6% |
Asset Composition Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Akari Therapeutics PLC stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akari Therapeutics PLC's current assets represent 11.4% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2025, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 87.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 71.0% of total assets.
Akari Therapeutics PLC Competitors by Total Assets
Key competitors of Akari Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Akari Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.44 | 0.15 | 2.00 |
| Quick Ratio | 0.44 | 0.15 | 2.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.89 Million | $-16.96 Million | $3.91 Million |
Akari Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Akari Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | $47.89 Million |
| Market Capitalization | $7.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Akari Therapeutics PLC's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Akari Therapeutics PLC's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Akari Therapeutics PLC (2010–2025)
The table below shows the annual total assets of Akari Therapeutics PLC from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $47.89 Million | -5.28% |
| 2024-12-31 | $50.56 Million | +1061.01% |
| 2023-12-31 | $4.36 Million | -68.52% |
| 2022-12-31 | $13.83 Million | +18.75% |
| 2021-12-31 | $11.65 Million | -20.25% |
| 2020-12-31 | $14.60 Million | +41.70% |
| 2019-12-31 | $10.31 Million | -37.35% |
| 2018-12-31 | $16.45 Million | -43.37% |
| 2017-12-31 | $29.05 Million | -36.67% |
| 2016-12-31 | $45.87 Million | -34.37% |
| 2015-12-31 | $69.89 Million | +978.60% |
| 2014-12-31 | $6.48 Million | -17.26% |
| 2013-12-31 | $7.83 Million | +599.29% |
| 2012-12-31 | $1.12 Million | +4048.15% |
| 2011-12-31 | $27.00K | -21.55% |
| 2010-12-31 | $34.42K | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more